ClinVar Miner

Submissions for variant NM_007294.4(BRCA1):c.2060A>C (p.Gln687Pro) (rs28897680)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 7
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000047696 SCV000075709 likely benign Hereditary breast and ovarian cancer syndrome 2020-11-12 criteria provided, single submitter clinical testing
Ambry Genetics RCV000129968 SCV000184792 uncertain significance Hereditary cancer-predisposing syndrome 2018-11-14 criteria provided, single submitter clinical testing The p.Q687P variant (also known as c.2060A>C), located in coding exon 9 of the BRCA1 gene, results from an A to C substitution at nucleotide position 2060. The glutamine at codon 687 is replaced by proline, an amino acid with similar properties. This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. <br />
GeneDx RCV000587889 SCV000565959 uncertain significance not provided 2018-08-28 criteria provided, single submitter clinical testing This variant is denoted BRCA1 c.2060A>C at the cDNA level, p.Gln687Pro (Q687P) at the protein level, and results in the change of a Glutamine to a Proline (CAG>CCG). This variant, also known as BRCA1 2179A>C using alternate nomenclature, has not, to our knowledge, been published in the literature as a germline pathogenic or benign variant; however, it has been reported as a somatic variant in a lung and ovarian tumor (Kan 2010, Ellison 2015). BRCA1 Gln687Pro was not observed at a significant allele frequency in large population cohorts (Lek 2016). Since Glutamine and Proline differ in polarity, charge, size or other properties, this is considered a non-conservative amino acid substitution. BRCA1 Gln687Pro is located in the DNA-binding domain and the RAD50 and STAT1 binding domains (Zhong 1999, Ouchi 2000, Narod 2004). In-silico analyses, including protein predictors and evolutionary conservation, support a deleterious effect. Based on currently available evidence, it is unclear whether BRCA1 Gln687Pro is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Color Health, Inc RCV000129968 SCV000683009 uncertain significance Hereditary cancer-predisposing syndrome 2019-02-01 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000587889 SCV000698913 uncertain significance not provided 2017-05-15 criteria provided, single submitter clinical testing Variant summary: The BRCA1 c.2060A>C (p.Gln687Pro) variant involves the alteration of a non-conserved nucleotide and is not located in some of the known domains in the protein (UniProt, InterPro). However, 4/5 in silico tools predict a damaging outcome for this variant. This variant was found in 1/121354 control chromosomes from ExAC at a frequency of 0.0000082, which does not exceed the estimated maximal expected allele frequency of a pathogenic BRCA1 variant (0.0010005). It has been reported in literature in one case with ovarian cancer without strong evidence for or against pathogenicity (Ellison_2015). Majority of submissions (4 out of 5) in ClinVar from clinical diagnostic laboratories/reputable databases consider this variant as uncertain significance. Taken together, this variant is currently classified as Variant of Unknown Significance (VUS).
Sharing Clinical Reports Project (SCRP) RCV000031024 SCV000053617 likely benign Breast-ovarian cancer, familial 1 2010-03-15 no assertion criteria provided clinical testing
Breast Cancer Information Core (BIC) (BRCA1) RCV000031024 SCV000144283 uncertain significance Breast-ovarian cancer, familial 1 2002-05-29 no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.